A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C

A. Obaid Shakil, Brendon McGuire, Jeff Crippin, Lewis Teperman, A. Jake Demetris, Hari Conjeevaram, Robert Gish, Paul Kwo, Vijayan Balan, Teresa L. Wright, Clifford Brass, Jorge Rakela

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Although interferon alfa (IFN-α) and ribavirin are widely used in the treatment of hepatitis C, their role in the transplant recipient is unclear. We conducted a pilot study to determine the efficacy and safety of this therapy in transplant recipients with recurrent hepatitis C. Patients at least 6 months posttransplantation were treated with IFN-α 3 million units 3 times a week subcutaneously and ribavirin 800 mg daily by mouth for 48 weeks followed by ribavirin monotherapy for 24 weeks. The primary end point was sustained virologic response, and secondary end points included biochemical, virologic, and histologic responses at the end of combination treatment. Thirty-eight patients initiated therapy but 16 withdrew due to adverse effects, including 2 with myocardial infarction. Median age was 50 years; 74% were men, and 91% had genotype 1. The median interval between transplantation and enrollment was 23 months. On an intention-to-treat basis, 7 patients (18%) had a biochemical and 5 (13%) had a virologic response at the end of combination treatment. Inflammatory activity did not change, but fibrosis worsened in virologic nonresponders. Ribavirin maintenance caused a further decrease in serum alanine aminotransferase levels, but hepatitis C virus (HCV) RNA levels increased. Only 2 of the 38 patients (5%) had a sustained virologic response. Several patients required treatment with erythropoietin for anemia. In conclusion, IFN-α and ribavirin are effective in a small proportion of liver allograft recipients with recurrent hepatitis C. Adverse effects occur commonly, requiring dose reductions and treatment withdrawal.

Original languageEnglish (US)
Pages (from-to)1253-1258
Number of pages6
JournalHepatology
Volume36
Issue number5 II
DOIs
StatePublished - Nov 1 2002

Fingerprint

Ribavirin
Hepatitis C
Interferon-alpha
Liver
Therapeutics
Erythropoietin
Transplant Recipients
Alanine Transaminase
Hepacivirus
Allografts
Mouth
Anemia
Fibrosis
Transplantation
Myocardial Infarction
Genotype
Maintenance
RNA
Safety
Serum

ASJC Scopus subject areas

  • Hepatology

Cite this

Shakil, A. O., McGuire, B., Crippin, J., Teperman, L., Demetris, A. J., Conjeevaram, H., ... Rakela, J. (2002). A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology, 36(5 II), 1253-1258. https://doi.org/10.1053/jhep.2002.36162

A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. / Shakil, A. Obaid; McGuire, Brendon; Crippin, Jeff; Teperman, Lewis; Demetris, A. Jake; Conjeevaram, Hari; Gish, Robert; Kwo, Paul; Balan, Vijayan; Wright, Teresa L.; Brass, Clifford; Rakela, Jorge.

In: Hepatology, Vol. 36, No. 5 II, 01.11.2002, p. 1253-1258.

Research output: Contribution to journalArticle

Shakil, AO, McGuire, B, Crippin, J, Teperman, L, Demetris, AJ, Conjeevaram, H, Gish, R, Kwo, P, Balan, V, Wright, TL, Brass, C & Rakela, J 2002, 'A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C', Hepatology, vol. 36, no. 5 II, pp. 1253-1258. https://doi.org/10.1053/jhep.2002.36162
Shakil AO, McGuire B, Crippin J, Teperman L, Demetris AJ, Conjeevaram H et al. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology. 2002 Nov 1;36(5 II):1253-1258. https://doi.org/10.1053/jhep.2002.36162
Shakil, A. Obaid ; McGuire, Brendon ; Crippin, Jeff ; Teperman, Lewis ; Demetris, A. Jake ; Conjeevaram, Hari ; Gish, Robert ; Kwo, Paul ; Balan, Vijayan ; Wright, Teresa L. ; Brass, Clifford ; Rakela, Jorge. / A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. In: Hepatology. 2002 ; Vol. 36, No. 5 II. pp. 1253-1258.
@article{5a1cf1a0ebbd4ad492a2446596d5fff1,
title = "A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C",
abstract = "Although interferon alfa (IFN-α) and ribavirin are widely used in the treatment of hepatitis C, their role in the transplant recipient is unclear. We conducted a pilot study to determine the efficacy and safety of this therapy in transplant recipients with recurrent hepatitis C. Patients at least 6 months posttransplantation were treated with IFN-α 3 million units 3 times a week subcutaneously and ribavirin 800 mg daily by mouth for 48 weeks followed by ribavirin monotherapy for 24 weeks. The primary end point was sustained virologic response, and secondary end points included biochemical, virologic, and histologic responses at the end of combination treatment. Thirty-eight patients initiated therapy but 16 withdrew due to adverse effects, including 2 with myocardial infarction. Median age was 50 years; 74{\%} were men, and 91{\%} had genotype 1. The median interval between transplantation and enrollment was 23 months. On an intention-to-treat basis, 7 patients (18{\%}) had a biochemical and 5 (13{\%}) had a virologic response at the end of combination treatment. Inflammatory activity did not change, but fibrosis worsened in virologic nonresponders. Ribavirin maintenance caused a further decrease in serum alanine aminotransferase levels, but hepatitis C virus (HCV) RNA levels increased. Only 2 of the 38 patients (5{\%}) had a sustained virologic response. Several patients required treatment with erythropoietin for anemia. In conclusion, IFN-α and ribavirin are effective in a small proportion of liver allograft recipients with recurrent hepatitis C. Adverse effects occur commonly, requiring dose reductions and treatment withdrawal.",
author = "Shakil, {A. Obaid} and Brendon McGuire and Jeff Crippin and Lewis Teperman and Demetris, {A. Jake} and Hari Conjeevaram and Robert Gish and Paul Kwo and Vijayan Balan and Wright, {Teresa L.} and Clifford Brass and Jorge Rakela",
year = "2002",
month = "11",
day = "1",
doi = "10.1053/jhep.2002.36162",
language = "English (US)",
volume = "36",
pages = "1253--1258",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "5 II",

}

TY - JOUR

T1 - A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C

AU - Shakil, A. Obaid

AU - McGuire, Brendon

AU - Crippin, Jeff

AU - Teperman, Lewis

AU - Demetris, A. Jake

AU - Conjeevaram, Hari

AU - Gish, Robert

AU - Kwo, Paul

AU - Balan, Vijayan

AU - Wright, Teresa L.

AU - Brass, Clifford

AU - Rakela, Jorge

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Although interferon alfa (IFN-α) and ribavirin are widely used in the treatment of hepatitis C, their role in the transplant recipient is unclear. We conducted a pilot study to determine the efficacy and safety of this therapy in transplant recipients with recurrent hepatitis C. Patients at least 6 months posttransplantation were treated with IFN-α 3 million units 3 times a week subcutaneously and ribavirin 800 mg daily by mouth for 48 weeks followed by ribavirin monotherapy for 24 weeks. The primary end point was sustained virologic response, and secondary end points included biochemical, virologic, and histologic responses at the end of combination treatment. Thirty-eight patients initiated therapy but 16 withdrew due to adverse effects, including 2 with myocardial infarction. Median age was 50 years; 74% were men, and 91% had genotype 1. The median interval between transplantation and enrollment was 23 months. On an intention-to-treat basis, 7 patients (18%) had a biochemical and 5 (13%) had a virologic response at the end of combination treatment. Inflammatory activity did not change, but fibrosis worsened in virologic nonresponders. Ribavirin maintenance caused a further decrease in serum alanine aminotransferase levels, but hepatitis C virus (HCV) RNA levels increased. Only 2 of the 38 patients (5%) had a sustained virologic response. Several patients required treatment with erythropoietin for anemia. In conclusion, IFN-α and ribavirin are effective in a small proportion of liver allograft recipients with recurrent hepatitis C. Adverse effects occur commonly, requiring dose reductions and treatment withdrawal.

AB - Although interferon alfa (IFN-α) and ribavirin are widely used in the treatment of hepatitis C, their role in the transplant recipient is unclear. We conducted a pilot study to determine the efficacy and safety of this therapy in transplant recipients with recurrent hepatitis C. Patients at least 6 months posttransplantation were treated with IFN-α 3 million units 3 times a week subcutaneously and ribavirin 800 mg daily by mouth for 48 weeks followed by ribavirin monotherapy for 24 weeks. The primary end point was sustained virologic response, and secondary end points included biochemical, virologic, and histologic responses at the end of combination treatment. Thirty-eight patients initiated therapy but 16 withdrew due to adverse effects, including 2 with myocardial infarction. Median age was 50 years; 74% were men, and 91% had genotype 1. The median interval between transplantation and enrollment was 23 months. On an intention-to-treat basis, 7 patients (18%) had a biochemical and 5 (13%) had a virologic response at the end of combination treatment. Inflammatory activity did not change, but fibrosis worsened in virologic nonresponders. Ribavirin maintenance caused a further decrease in serum alanine aminotransferase levels, but hepatitis C virus (HCV) RNA levels increased. Only 2 of the 38 patients (5%) had a sustained virologic response. Several patients required treatment with erythropoietin for anemia. In conclusion, IFN-α and ribavirin are effective in a small proportion of liver allograft recipients with recurrent hepatitis C. Adverse effects occur commonly, requiring dose reductions and treatment withdrawal.

UR - http://www.scopus.com/inward/record.url?scp=0036829821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036829821&partnerID=8YFLogxK

U2 - 10.1053/jhep.2002.36162

DO - 10.1053/jhep.2002.36162

M3 - Article

C2 - 12395337

AN - SCOPUS:0036829821

VL - 36

SP - 1253

EP - 1258

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 5 II

ER -